Trade Names:Xibrom- Solution 0.09%
Decreases inflammation by blocking prostaglandin synthesis through inhibition of cyclooxygenase 1 and 2.
Based on the recommended ophthalmic dose, systemic plasma concentration is estimated to be below the limit of quantification (50 ng/mL).
Treatment of postoperative inflammation in patients who have undergone cataract extraction.
Ophthalmic 1 drop to affected eye(s) twice daily beginning 24 h after cataract surgery and continuing postoperatively through the first 2 wk.
Store ophthalmic solution between 59° and 77°F. Keep tightly capped.
None well documented.
None well documented.
Headache (2% to 7%).
Abnormal sensation in eye, conjunctival hyperemia, eye irritation (including burning/stinging), eye pain, eye pruritus, eye redness, iritis (2% to 7%); corneal erosion, corneal perforation, corneal thinning, epithelial breakdown (postmarketing).
Category C .
Use with caution.
Safety and efficacy not established.
Because of potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, use with caution in patients who previously have exhibited sensitivity to these drugs.
There is a potential for increased bleeding time because of interference with platelet aggregation. Use with caution in patients with known bleeding tendencies or who are receiving other medications that prolong bleeding time
May slow or delay healing.
Continued use may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation, which may threaten sight.
Because of increased risk of corneal adverse reactions, use with caution in patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (eg, dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time. Risk of corneal adverse reactions also may be increased if topical NSAIDs are used more than 24 h prior to surgery or beyond 14 days postsurgery.
Contains sodium sulfite, which may cause allergic-type reactions including asthmatic episodes and life-threatening anaphylaxis.
Copyright © 2009 Wolters Kluwer Health.